JAJennifer Austin

Jennifer Austin

*This is an algorithmically generated author record based on publicly available information.

Jennifer Austin has a total of 50 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    The worldwide burden of skin diseases: Lessons from the Global Burden of Disease data

    by Luigi Naldi, Simone Cazzaniga, Carsten Flohr, Marco May Lee, Claire Fuller, Roderick Hay, Esther E. Freeman, Rashmi Sarkar, Ricardo Romiti, Antonio Torrelo, et al.

    Background: Skin diseases represent a major public health concern, affecting all demographics and imposing significant personal, economic and social burdens. Objectives: To assess the epidemiology and impact of skin diseases using the Global Burden of Disease (GBD) data, highlighting regional variations, knowledge gaps and areas for improvement. Methods: GBD data on prevalence, incidence, disability‐adjusted life years (DALYs) and years lived with disability (YLDs) for skin conditions from 2000 to 2021 were analysed. Results: According to GBD 2021, the global prevalence of skin and subcutaneous diseases, excluding sexually transmitted infections (STIs) and skin cancers, was 25.7%, ranking sixth among the most prevalent disease categories worldwide. These conditions accounted for a global YLDs rate of 495.1 per 100,000 person‐years, placing them eighth in terms of disease burden. Overall, the most prevalent conditions were STIs excluding HIV (16.8%), fungal infections (7.8%), and acne (3.0%). Squamous cell carcinoma, basal cell carcinoma and decubitus ulcers showed increasing prevalence, while atopic dermatitis, scabies and viral infections declined slightly. Acne, scabies and atopic dermatitis predominated in youth, whereas fungal infections, contact dermatitis and skin cancers predominated in older adults. Females showed higher prevalence of STIs, acne and atopic dermatitis. Infectious skin diseases were more common in Sub‐Saharan Africa and tropical regions, while chronic inflammatory and neoplastic diseases predominated in high‐income regions. Conclusions: Several limitations were identified. The GBD initiative only includes some dermatological diseases reflecting the difficulties in obtaining data because of the multitude of skin diseases with underreporting and misdiagnosis. There are significant gaps in data from low‐ and middle‐income countries, a lack of reliable trends and inadequate quality‐adjusted life year estimates considering cultural and social variations. The GBD initiative provides valuable insights but underestimates the true burden of skin diseases. Improved reporting and inclusion of neglected conditions are urgently needed through global collaboration among stakeholders.


  • A European Roundtable “Addressing Under-Prioritized Skin Diseases: Policy Responses to High-Burden Conditions”

    by Yalchin Mammadov, Jennifer Austin, Tammi Shipowick, Karin Veldman, Sabine Eming, Andrea Szegedi, Eli Sprecher, Curdin Conrad


  • Open Access

    Measurement properties and interpretability of the Patient-Reported Impact of Dermatological Diseases (PRIDD) measure

    by Rachael Pattinson, Nirohshah Trialonis-Suthakharan, Tim Pickles, Jennifer Austin, Allison FitzGerald, Matthias Augustin, Christine Bundy

    Background: Patient-reported outcome measures (PROMs) are crucial in assessing the impact of dermatological conditions on people’s lives, but the existing dermatology-specific PROMs are not recommended for use, according to COSMIN. We developed the Patient-Reported Impact of Dermatological Diseases (PRIDD) measure in partnership with patients. It has strong evidence of content validity, structural validity, internal consistency, acceptability and feasibility. Objectives: To test the remaining measurement properties of the PRIDD and establish the interpretability of scores against the COSMIN criteria, using classic and modern psychometric methods. Methods: A global longitudinal study consisting of two online surveys administered 2–4 weeks apart was carried out. Adults (≥ 18 years of age) living with a dermatological condition were recruited via the International Alliance of Dermatology Patient Organizations’ (GlobalSkin) membership network. Participants completed PRIDD, a demographics questionnaire and other related measures, including the Dermatology Life Quality Index. We tested the criterion validity, construct validity and responsiveness (Spearman’s ρ, independent-samples t-tests and Anova); test–retest reliability [interclass correlation coefficient (ICC)]; measurement error [smallest detectable change or limits of agreement (LoA), distribution-based minimally important change (MIC)]; floor and ceiling effects (number of minimum and maximum scores and person–item location distribution maps), score bandings (κ coefficient of agreement) and the anchor-based MIC of the PRIDD. Results: In total, 504 people with 35 dermatological conditions from 38 countries participated. Criterion validity (ρ = 0.79), construct validity (76% hypotheses met), test–retest validity (ICC = 0.93) and measurement error (LoA = 1.3 < MIC = 4.14) were sufficient. Floor and ceiling effects were in the acceptable range (< 15%). Score bandings were determined (κ = 0.47); however, the anchor-based MIC could not be calculated owing to an insufficient anchor. Conclusions: PRIDD is a valid and reliable tool to evaluate the impact of dermatological disease on people’s lives in research and clinical practice. It is the first dermatology-specific PROM to meet the COSMIN criteria. These results support the value of developing and validating PROMs with a patient-centred approach and using classic and modern psychometric methods. Further testing of responsiveness and MIC, cross-cultural translation, linguistic validation and global data collection are planned.


  • Open Access

    Patient prioritisation of items to develop the Patient‐Reported Impact of Dermatological Diseases measure: A global Delphi study

    by Nirohshah Trialonis‐Suthakharan, Rachael Pattinson, Nasim Tahmasebi Gandomkari, Jennifer Austin, Christine Janus, Nick Courtier, Rachael M. Hewitt, Chris Bundy, Matthias Augustin

    Background: The Global Research on the Impact of Dermatological Diseases (GRIDD) project is developing the new Patient‐Reported Impact of Dermatological Diseases (PRIDD) measure. PRIDD measures the impact of dermatological conditions on the patient's life.Objectives: This study aimed to seek consensus from patients on which items to prioritize for inclusion in PRIDD.Methods: A modified, two‐round Delphi study was conducted. Adults (≥18 years) with dermatological conditions were recruited. The survey consisted of a demographic's questionnaire and 263 potential impact items in six languages. Quantitative data used Likert‐type ranking scales and analysed against consensus criteria. Qualitative data collected free text responses for additional feedback and a framework analysis was conducted.Results: 1154 people representing 90 dermatological conditions from 66 countries participated. Items were either removed (n = 79), edited (n = 179) or added (n = 2), based on consensus thresholds and qualitative feedback. Results generated the first draft of PRIDD with 27 items across five impact domains.Conclusion: This Delphi study resulted in the draft version of PRIDD, ready for psychometric testing. The triangulated data helped refine the existing conceptual framework of impact. PRIDD has since been pilot tested with patients and is currently undergoing psychometric testing.


  • Open Access

    Patient prioritisation of impact items to develop the patient‐reported impact of dermatological diseases (PRIDD) measure: European Delphi data

    by N. Trialonis‐Suthakharan, R. Pattinson, N. Tahmasebi Gandomkari, J. Austin, C. Janus, N. Courtier, R. M. Hewitt, C. Bundy, M. Augustin

    Background: The Global Research on the Impact of Dermatological Diseases (GRIDD) project is developing a patient‐reported measure of the impact of dermatological disease on the patient's life called Patient Reported Impact of Dermatological Diseases (PRIDD). We developed a list of 263 potential impact items through a global qualitative interview study with 68 patients. We next conducted a Delphi study to seek consensus on which of these items to prioritize for inclusion in PRIDD. This study aims to explore patterns in demographic (e.g. country) and clinical variables (e.g. disease group) across the impacts ranked as most important to European dermatology patients.Methods: We conducted a modified, two rounds Delphi study, testing the outcomes from the previous qualitative interview study. Adults (≥18 years) living with a dermatological disease were recruited through the International Alliance of Dermatology Patient Organizations' (GlobalSkin) membership network. The survey consisted of a demographic questionnaire and 263 impact items and was available in six languages. Quantitative data were collected using ranking scales and analysed against a priori consensus criteria. Qualitative data were collected using free‐text responses and a Framework Analysis was conducted. European data were obtained, and descriptive statistics, including multiple subgroup analyses, were performed.Results: Out of 1154 participants, 441 Europeans representing 46 dermatological disease from 25 countries participated. The results produced a list of the top 20 impacts reported by European patients, with psychological impacts accounting for the greatest proportion.Conclusion: This study identified what patients consider to be the most important issues impacting their lives as a result of their dermatological disease. The data support previous evidence that patients experience profound psychological impacts and require psychological support. The findings can inform research, clinical practice and policy by indicating research questions and initiatives that are of most benefit to patients.


  • Open Access

    The IRDiRC Chrysalis Task Force: making rare disease research attractive to companies

    by Katherine L. Beaverson, Daria Julkowska, Mary Catherine V. Letinturier, Annemieke Aartsma-Rus, Jennifer Austin, Juan Bueren, Simon Frost, Misako Hamamura, Jane Larkindale, Greg LaRosa, et al.

    Background: The International Rare Diseases Research Consortium (IRDiRC) is an international initiative that aims to use research to facilitate rapid diagnosis and treatment of rare diseases. Objective: IRDiRC launched the Chrysalis Task Force to identify key financial and nonfinancial factors that make rare disease research and development attractive to companies. Methods: The Chrysalis Task Force was comprised of thought leaders from companies, patient advocacy groups, regulatory agencies, and research funders. The Task Force created a survey that was distributed to companies of different sizes with varied investment portfolios and interests in rare disease research. Based on the survey results, the Task Force then conducted targeted interviews. Results: The survey and interview respondents identified several factors that make rare disease research and development attractive (e.g. a good understanding of the underlying biology) as well as barriers (e.g. absence of an advocacy organization representing the affected community’s needs). The concept of Return On Investment allowed the exploration of factors that were weighed differently by survey and interview respondents, depending on a number of intrinsic and extrinsic issues. Conclusions: The Chrysalis Task Force identified factors attributable to rare disease research and development that may be of interest to and actionable by funders, academic researchers, patients and their families, companies, regulators, and payers in the medium term to short term. By addressing the identified challenges, involved parties may seek solutions to significantly advance the research and development of treatments for rare diseases.